Overview / Newsletter / 2026-09

BIOPOLYMER Monthly — September 2026 (trial issue skeleton)

status: draftskeletonreviewer: OPEN (G4)cutoff 30 Sept 2026

Trial issue. Only the Avantium item is evidence-checked; nothing is signed. The technical reviewer, delivery date and distribution channel are still OPEN (G4).
Cross-issue novelty could not be checked — first issue.
September triage stopped at the 60-call budget: records still marked 'triage pending' may contain further candidates.
Evidence-checked by the build editor on 2026-10-20 from Avantium's own releases; three syndicated news reports of the same start-up were collapsed onto them. Not signed.
Issue stays 'draft' until the two remaining shortlisted leads are checked or dropped and a reviewer signs.

Build checks

Rendered pages: 2 (max 2 A4)
Words: 512 (350–500 required once the issue is final)
Body text: 10.5 pt
Problems: none
Built: 2026-10-20T19:00:34+00:00

What changed this month

One development passed the evidence check: Avantium's first FDCA batch at a commercial-scale plant, a supply milestone for PEF. Two shortlisted research leads, a PLA/PA11 blend and a PHBV strain study, still await their evidence check.

Shortlist for evidence checking

Up to three machine-triaged leads selected for a human evidence check. Their evidence records are empty until the primary source is read; nothing below is verified beyond the quote.

Why shortlisted: PLA route, formulation: peer-reviewed PLA/PA11 blend with a bio-based compatibiliser; relevant to toughness for durable parts. · evidence record empty — full text not yet read

machine-triagedPLA, lactide copolymers & blendsFormulation / application21 Sept 2026· Industrial & Engineering Chemistry Researchjournal

Simultaneous Compatibilization and Toughening of Renewable PLA/PA11 Blend via Core-Shell Biobased Nanosilica-Filled Elastomer

The study compatibilizes and toughens a renewable PLA/PA11 blend using a biobased amino-functionalized nanosilica/epoxy elastomer hybrid.

doi:10.1021/acs.iecr.6c03874

Why shortlisted: PHA route, new production route: peer-reviewed strain work on raising 3-hydroxyvalerate content in PHBV. · evidence record empty — full text not yet read

machine-triagedPHA family & copolymersNew routeSept 2026· International Journal of Biological Macromoleculesjournaltitle only

Enhancing 3-hydroxyvalerate concentration in poly(3-hydroxybutyrate-co-3-hydroxyvalerate) by Pseudomonas aeruginosa strain 78B using volatile fatty acids with papermill effluent blackliquor

Pseudomonas aeruginosa strain 78B was used with volatile fatty acids and papermill effluent black liquor to raise 3-hydroxyvalerate content in PHBV.

“Enhancing 3-hydroxyvalerate concentration in poly(3-hydroxybutyrate-co-3-hydroxyvalerate) by Pseudomonas aeruginosa strain 78B” (title)

doi:10.1016/j.ijbiomac.2026.153504

Watchlist

Avantium FDCA plant: batch-to-continuous operation and first commercial deliveries (company expects end of 2026).

Follow-up questions

What design capacity and actual output will Avantium report once the plant runs continuously?
Which system boundary and functional unit underlie Avantium's PEF footprint claims?